Trial · NCT02709889
Results by group232
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 232
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Summary of Treatment-Emergent Adverse Events (TEAEs), by Dose and Neuroendocrine (NEC) or Non-NEC Disease Groups | NEC: 0.2 mg/kg | ≥ 1 TEAE | 24 | participants | |
| Summary of Treatment-Emergent Adverse Events (TEAEs), by Dose and Neuroendocrine (NEC) or Non-NEC Disease Groups | NEC: 0.3 mg/kg | ≥ 1 TEAE | 69 | participants | |
| Summary of Treatment-Emergent Adverse Events (TEAEs), by Dose and Neuroendocrine (NEC) or Non-NEC Disease Groups | NEC: 0.4 mg/kg | ≥ 1 TEAE | 8 | participants | |
| Summary of Treatment-Emergent Adverse Events (TEAEs), by Dose and Neuroendocrine (NEC) or Non-NEC Disease Groups | NEC: Any Dose | ≥ 1 TEAE | 101 | participants | |
| Summary of Treatment-Emergent Adverse Events (TEAEs), by Dose and Neuroendocrine (NEC) or Non-NEC Disease Groups | Non-NEC: 0.2 mg/kg | ≥ 1 TEAE | 18 | participants | |
| Summary of Treatment-Emergent Adverse Events (TEAEs), by Dose and Neuroendocrine (NEC) or Non-NEC Disease Groups | Non-NEC: 0.3 mg/kg | ≥ 1 TEAE | 75 | participants | |
| Summary of Treatment-Emergent Adverse Events (TEAEs), by Dose and Neuroendocrine (NEC) or Non-NEC Disease Groups | Non-NEC: 0.4 mg/kg | ≥ 1 TEAE | 4 | participants | |
| Summary of Treatment-Emergent Adverse Events (TEAEs), by Dose and Neuroendocrine (NEC) or Non-NEC Disease Groups | Non-NEC: Any Dose | ≥ 1 TEAE | 97 | participants | |
| Summary of Treatment-Emergent Adverse Events (TEAEs), by Dose and Neuroendocrine (NEC) or Non-NEC Disease Groups | NEC: 0.2 mg/kg | ≥ 1 TEAE, Grade 3-4 | 20 | participants | |
| Summary of Treatment-Emergent Adverse Events (TEAEs), by Dose and Neuroendocrine (NEC) or Non-NEC Disease Groups | NEC: 0.3 mg/kg | ≥ 1 TEAE, Grade 3-4 | 40 | participants | |
| Summary of Treatment-Emergent Adverse Events (TEAEs), by Dose and Neuroendocrine (NEC) or Non-NEC Disease Groups | NEC: 0.4 mg/kg | ≥ 1 TEAE, Grade 3-4 | 5 | participants | |
| Summary of Treatment-Emergent Adverse Events (TEAEs), by Dose and Neuroendocrine (NEC) or Non-NEC Disease Groups | NEC: Any Dose | ≥ 1 TEAE, Grade 3-4 | 65 | participants | |
| Summary of Treatment-Emergent Adverse Events (TEAEs), by Dose and Neuroendocrine (NEC) or Non-NEC Disease Groups | Non-NEC: 0.2 mg/kg | ≥ 1 TEAE, Grade 3-4 | 10 | participants | |
| Summary of Treatment-Emergent Adverse Events (TEAEs), by Dose and Neuroendocrine (NEC) or Non-NEC Disease Groups | Non-NEC: 0.3 mg/kg | ≥ 1 TEAE, Grade 3-4 | 38 | participants | |
| Summary of Treatment-Emergent Adverse Events (TEAEs), by Dose and Neuroendocrine (NEC) or Non-NEC Disease Groups | Non-NEC: 0.4 mg/kg | ≥ 1 TEAE, Grade 3-4 | 4 | participants | |
| Summary of Treatment-Emergent Adverse Events (TEAEs), by Dose and Neuroendocrine (NEC) or Non-NEC Disease Groups | Non-NEC: Any Dose | ≥ 1 TEAE, Grade 3-4 | 52 | participants | |
| Summary of Treatment-Emergent Adverse Events (TEAEs), by Dose and Neuroendocrine (NEC) or Non-NEC Disease Groups | NEC: 0.2 mg/kg | ≥ 1 TEAE, Grade 5 | 1 | participants | |
| Summary of Treatment-Emergent Adverse Events (TEAEs), by Dose and Neuroendocrine (NEC) or Non-NEC Disease Groups | NEC: 0.3 mg/kg | ≥ 1 TEAE, Grade 5 | 13 | participants | |
| Summary of Treatment-Emergent Adverse Events (TEAEs), by Dose and Neuroendocrine (NEC) or Non-NEC Disease Groups | NEC: 0.4 mg/kg | ≥ 1 TEAE, Grade 5 | 2 | participants | |
| Summary of Treatment-Emergent Adverse Events (TEAEs), by Dose and Neuroendocrine (NEC) or Non-NEC Disease Groups | NEC: Any Dose | ≥ 1 TEAE, Grade 5 | 16 | participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02709889/results